PMC:7074432 / 1785-2621 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"97","span":{"begin":92,"end":100},"obj":"Species"},{"id":"98","span":{"begin":149,"end":157},"obj":"Species"},{"id":"99","span":{"begin":191,"end":199},"obj":"Species"},{"id":"100","span":{"begin":213,"end":228},"obj":"Species"},{"id":"101","span":{"begin":349,"end":357},"obj":"Species"},{"id":"102","span":{"begin":418,"end":426},"obj":"Species"},{"id":"103","span":{"begin":479,"end":488},"obj":"Species"},{"id":"104","span":{"begin":55,"end":64},"obj":"Species"},{"id":"105","span":{"begin":167,"end":178},"obj":"Chemical"},{"id":"106","span":{"begin":261,"end":272},"obj":"Chemical"},{"id":"107","span":{"begin":309,"end":320},"obj":"Chemical"},{"id":"108","span":{"begin":403,"end":414},"obj":"Chemical"},{"id":"109","span":{"begin":432,"end":443},"obj":"Chemical"},{"id":"126","span":{"begin":822,"end":829},"obj":"Gene"},{"id":"127","span":{"begin":670,"end":678},"obj":"Species"}],"attributes":[{"id":"A97","pred":"tao:has_database_id","subj":"97","obj":"Tax:1335626"},{"id":"A98","pred":"tao:has_database_id","subj":"98","obj":"Tax:9606"},{"id":"A99","pred":"tao:has_database_id","subj":"99","obj":"Tax:9606"},{"id":"A100","pred":"tao:has_database_id","subj":"100","obj":"Tax:11309"},{"id":"A101","pred":"tao:has_database_id","subj":"101","obj":"Tax:1335626"},{"id":"A102","pred":"tao:has_database_id","subj":"102","obj":"Tax:1335626"},{"id":"A103","pred":"tao:has_database_id","subj":"103","obj":"Tax:2697049"},{"id":"A104","pred":"tao:has_database_id","subj":"104","obj":"Tax:11309"},{"id":"A105","pred":"tao:has_database_id","subj":"105","obj":"MESH:D053139"},{"id":"A106","pred":"tao:has_database_id","subj":"106","obj":"MESH:D053139"},{"id":"A107","pred":"tao:has_database_id","subj":"107","obj":"MESH:D053139"},{"id":"A108","pred":"tao:has_database_id","subj":"108","obj":"MESH:D053139"},{"id":"A109","pred":"tao:has_database_id","subj":"109","obj":"MESH:D053139"},{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"Gene:10045"},{"id":"A127","pred":"tao:has_database_id","subj":"127","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T143","span":{"begin":670,"end":678},"obj":"SP_10"},{"id":"T142","span":{"begin":754,"end":762},"obj":"MOP:0000780"},{"id":"T141","span":{"begin":822,"end":826},"obj":"PR:000014815"},{"id":"T107","span":{"begin":9,"end":19},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T106","span":{"begin":92,"end":100},"obj":"SP_9"},{"id":"T105","span":{"begin":167,"end":178},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T104","span":{"begin":213,"end":222},"obj":"NCBITaxon:7719"},{"id":"T103","span":{"begin":223,"end":228},"obj":"NCBITaxon:10239"},{"id":"T102","span":{"begin":261,"end":272},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T101","span":{"begin":309,"end":320},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T100","span":{"begin":349,"end":357},"obj":"SP_9"},{"id":"T99","span":{"begin":403,"end":414},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T98","span":{"begin":418,"end":426},"obj":"SP_9"},{"id":"T97","span":{"begin":432,"end":443},"obj":"CHEBI:7798;CHEBI:7798"},{"id":"T96","span":{"begin":479,"end":488},"obj":"SP_7"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":812,"end":820},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":55,"end":64},"obj":"Disease"},{"id":"T14","span":{"begin":213,"end":222},"obj":"Disease"},{"id":"T15","span":{"begin":670,"end":678},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T8","span":{"begin":72,"end":73},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T9","span":{"begin":135,"end":136},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T10","span":{"begin":146,"end":148},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T11","span":{"begin":223,"end":228},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T12","span":{"begin":239,"end":241},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T13","span":{"begin":428,"end":430},"obj":"http://purl.obolibrary.org/obo/CLO_0053733"},{"id":"T14","span":{"begin":684,"end":686},"obj":"http://purl.obolibrary.org/obo/CLO_0052906"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T17","span":{"begin":9,"end":19},"obj":"Chemical"},{"id":"T18","span":{"begin":167,"end":178},"obj":"Chemical"},{"id":"T19","span":{"begin":261,"end":272},"obj":"Chemical"},{"id":"T20","span":{"begin":309,"end":320},"obj":"Chemical"},{"id":"T21","span":{"begin":403,"end":414},"obj":"Chemical"},{"id":"T22","span":{"begin":432,"end":443},"obj":"Chemical"},{"id":"T23","span":{"begin":581,"end":586},"obj":"Chemical"},{"id":"T24","span":{"begin":617,"end":626},"obj":"Chemical"},{"id":"T25","span":{"begin":812,"end":820},"obj":"Chemical"}],"attributes":[{"id":"A17","pred":"chebi_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A18","pred":"chebi_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A20","pred":"chebi_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A21","pred":"chebi_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A22","pred":"chebi_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A23","pred":"chebi_id","subj":"T23","obj":"http://purl.obolibrary.org/obo/CHEBI_24433"},{"id":"A24","pred":"chebi_id","subj":"T24","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}

{"project":"LitCovid-sentences","denotations":[{"id":"T16","span":{"begin":188,"end":606},"obj":"Sentence"},{"id":"T17","span":{"begin":608,"end":626},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}

{"project":"2_test","denotations":[{"id":"32201439-30012113-47219407","span":{"begin":365,"end":367},"obj":"30012113"},{"id":"32201439-30882305-47219408","span":{"begin":428,"end":430},"obj":"30882305"},{"id":"32201439-31986264-47219409","span":{"begin":603,"end":605},"obj":"31986264"},{"id":"T19064","span":{"begin":365,"end":367},"obj":"30012113"},{"id":"T33497","span":{"begin":428,"end":430},"obj":"30882305"},{"id":"T42850","span":{"begin":603,"end":605},"obj":"31986264"}],"text":"minidase inhibitors are indicated in the management of influenza.[9] In a study on possible MERS-CoV cases in Paris from 2013 to 2016, a total of 35 patients received oseltamivir (37.6%). In patients positive for influenza virus (n = 25), 52% (n = 13) received oseltamivir and it was concluded that empirical oseltamivir can be started in suspected MERS-CoV cases.[10] Many other studies also evaluated oseltamivir in MERS-CoV.[11] Oseltamivir was also used in the management of 2019-nCoV; however, definite evidence of efficacy is inconclusive because of lack of suitable control group in the studies.[12]\n\nProtease inhibitor\nThere are two types of protease present in SARS-CoV, the CL-like protease and the papain-like protease, which is important for cleaving the polyproteins and releasing the nonstructural proteins (NSP1–16), whic"}